Last reviewed · How we verify
NCT05175872: trauma
Factors Affecting Mortality and Morbidity in Trauma Patients Followed in Intensive Care Unit
trial in Trauma, Multiple in 194 participants. Completed in 15 October 2021.
15 October 2021
Quick facts
| Lead sponsor | Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 194 |
| Start date | 14 October 2019 |
| Primary completion | 15 October 2021 |
| Estimated completion | 15 October 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Trauma, Multiple — all drugs for Trauma, Multiple →
- Trauma Injury — all drugs for Trauma Injury →
Sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Who can join
18 and older, any sex, with Trauma, Multiple or Trauma Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the demographic and clinical characteristics of trauma patients followed up in the Intensive Care Unit of the Anesthesiology and Reanimation Clinic of the Health Sciences University Okmeydanı Training and Research Hospital for a 2-year period were evaluated prospectively to determine the morbidity and mortality rates and to determine the factors affecting these rates. data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05175872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Trauma, Multiple
Currently open trials in the same condition.
- NCT06709547 — Mortality Prediction Using Trauma Scores · recruiting
- NCT06305819 — Effectiveness of a Self-management Program After Traumatic Injury · NA · recruiting
- NCT05754190 — Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA · recruiting
- NCT03526029 — Swiss Trauma Registry · recruiting
Other Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization trials
Trials by the same sponsor.
- NCT07500285 — Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Ph · Phase 2 · not yet recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07390279 — Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia · recruiting
- NCT07357922 — Serum Progesterone and Threatened Abortion During Lactation · not yet recruiting
- NCT07283250 — Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05175872 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- Last refreshed: 4 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05175872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing